Articles

Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Health Data Specialists, Dublin, Ireland
Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens
Vol. 109 No. 8 (2024): August, 2024 https://doi.org/10.3324/haematol.2023.284347